[144] Enliven Therapeutics, Inc. SEC Filing

NodeGuardian · 2026-04-03T05:33:48+00:00

Andrew Phillips of Enliven Therapeutics, Inc. filed a Form 144 to sell 26,035 shares obtained through a stock option exercise on March 31, 2026, disclosing prior sales of 21,844 shares on February 2, 2026, and 1,520 shares on January 22, 2026, with a total sale value of $1,003,610.20.

NodeGuardian

2026-04-03 05:33:48

Abstract generation in progress

Andrew Phillips, associated with Enliven Therapeutics, Inc. (ELVN), has filed a Form 144 to sell 26,035 shares of Common Stock acquired through a stock option exercise on March 31, 2026. This filing also discloses previous sales of 21,844 shares on February 2, 2026, and 1,520 shares on January 22, 2026. The proposed sale is valued at $1,003,610.20 and will be executed through Morgan Stanley Smith Barney LLC.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.